FDA Approvals, Patient Selection, and SC Amivantamab

Panelists discuss how recent FDA approvals for subcutaneous (SC) oncology agents are expanding therapeutic flexibility. They highlight approvals for SC versions of atezolizumab, nivolumab, and pembrolizumab, as well as clinical data from the PALOMA trials evaluating SC amivantamab. The discussion reviews findings demonstrating equivalent efficacy, safety, and pharmacokinetics to intravenous (IV) formulations. Panelists also address patient selection criteria, clinical considerations for integrating SC therapies with IV regimens, and how these innovations enhance workflow efficiency and patient experience.